Voya Investment Management LLC lessened its holdings in Anika Therapeutics Inc. (NASDAQ:ANIK) by 56.5% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 7,499 shares of the biotechnology company’s stock after selling 9,751 shares during the quarter. Voya Investment Management LLC owned approximately 0.05% of Anika Therapeutics worth $370,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors have also made changes to their positions in ANIK. State of Alaska Department of Revenue grew its position in shares of Anika Therapeutics by 79.5% during the 2nd quarter. State of Alaska Department of Revenue now owns 2,872 shares of the biotechnology company’s stock worth $141,000 after buying an additional 1,272 shares in the last quarter. Municipal Employees Retirement System of Michigan grew its position in shares of Anika Therapeutics by 3.0% during the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 3,450 shares of the biotechnology company’s stock worth $170,000 after buying an additional 100 shares in the last quarter. Victory Capital Management Inc. boosted its position in Anika Therapeutics by 17.6% during the second quarter. Victory Capital Management Inc. now owns 4,060 shares of the biotechnology company’s stock valued at $200,000 after purchasing an additional 608 shares in the last quarter. BNP Paribas Arbitrage SA boosted its position in Anika Therapeutics by 3.0% during the second quarter. BNP Paribas Arbitrage SA now owns 4,315 shares of the biotechnology company’s stock valued at $213,000 after purchasing an additional 126 shares in the last quarter. Finally, Eagle Ridge Investment Management bought a new stake in Anika Therapeutics during the second quarter valued at about $214,000. 83.95% of the stock is currently owned by institutional investors.
ANIK has been the topic of a number of recent research reports. Zacks Investment Research raised Anika Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 2nd. BidaskClub raised Anika Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, August 8th. Finally, Barrington Research increased their price target on Anika Therapeutics from $53.00 to $57.00 and gave the company an “outperform” rating in a research note on Friday, October 27th.
In other Anika Therapeutics news, CEO Charles H. Sherwood sold 5,991 shares of Anika Therapeutics stock in a transaction on Friday, October 20th. The stock was sold at an average price of $60.04, for a total value of $359,699.64. Following the sale, the chief executive officer now owns 158,297 shares in the company, valued at $9,504,151.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Charles H. Sherwood sold 3,293 shares of Anika Therapeutics stock in a transaction on Monday, October 16th. The shares were sold at an average price of $60.04, for a total value of $197,711.72. The disclosure for this sale can be found here. Insiders sold 38,636 shares of company stock worth $2,320,435 over the last ninety days. Corporate insiders own 6.57% of the company’s stock.
Anika Therapeutics Inc. (ANIK) opened at $53.39 on Monday. The stock has a market capitalization of $782.79, a PE ratio of 25.07, a PEG ratio of 2.80 and a beta of 1.47. Anika Therapeutics Inc. has a 12 month low of $41.64 and a 12 month high of $60.29.
Anika Therapeutics (NASDAQ:ANIK) last issued its quarterly earnings data on Wednesday, October 25th. The biotechnology company reported $0.46 EPS for the quarter, beating the consensus estimate of $0.41 by $0.05. The company had revenue of $27.18 million for the quarter, compared to analyst estimates of $27.44 million. Anika Therapeutics had a return on equity of 13.40% and a net margin of 28.23%. Anika Therapeutics’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same period last year, the company earned $0.59 earnings per share. analysts forecast that Anika Therapeutics Inc. will post 1.9 EPS for the current fiscal year.
About Anika Therapeutics
Anika Therapeutics, Inc is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.
Receive News & Ratings for Anika Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.